US 9,808,440 B2
Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
Kunihiko Kiyono, Osaka (JP); Kenji Onishi, Osaka (JP); Yasuharu Nagahama, Osaka (JP); and Takashi Watanabe, Osaka (JP)
Assigned to RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD., Saitama-Pre (JP)
Appl. No. 14/893,127
Filed by OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
PCT Filed May 23, 2014, PCT No. PCT/JP2014/064354
§ 371(c)(1), (2) Date Nov. 23, 2015,
PCT Pub. No. WO2014/189152, PCT Pub. Date Nov. 27, 2014.
Claims priority of application No. 2013-110278 (JP), filed on May 24, 2013.
Prior Publication US 2016/0101082 A1, Apr. 14, 2016
Int. Cl. A61K 31/353 (2006.01); A61K 31/155 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 31/155 (2013.01); A61K 45/06 (2013.01)] 8 Claims
 
1. A method for treating a malignant tumor, comprising administering metformin or a pharmaceutically acceptable salt thereof, and dihydroquercetin or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein metformin or a pharmaceutically acceptable salt thereof, and dihydroquercetin or a pharmaceutically acceptable salt thereof are administered as a single preparation or separate preparations which are administered simultaneously or at different time points,
wherein the malignant tumor is lung cancer, pancreatic cancer, liver cancer, breast cancer, prostate cancer, bile duct cancer, or ovarian cancer.